NEWTON, J., E. N. D. PALLADINO, C. WEIGEL, M. MACEYKA, M. H. GRALER, C. E. SENKAL, R. D. ENRIZ, Pavlína MARVANOVÁ, J. JAMPILEK, S. LIMA, S. MILSTIEN a S. SPIEGEL. Targeting defective sphingosine kinase 1 in Niemann?Pick type C disease with an activator mitigates cholesterol accumulation. Journal of Biological Chemistry. Bethesda, USA: Amer. Soc. Biochem. Mol. Biol., 2020, roč. 295, č. 27, s. 9121-9133. ISSN 0021-9258. Dostupné z: https://dx.doi.org/10.1074/jbc.RA120.012659.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Targeting defective sphingosine kinase 1 in Niemann?Pick type C disease with an activator mitigates cholesterol accumulation
Autoři NEWTON, J., E. N. D. PALLADINO, C. WEIGEL, M. MACEYKA, M. H. GRALER, C. E. SENKAL, R. D. ENRIZ, Pavlína MARVANOVÁ (203 Česká republika, domácí), J. JAMPILEK, S. LIMA, S. MILSTIEN a S. SPIEGEL.
Vydání Journal of Biological Chemistry, Bethesda, USA, Amer. Soc. Biochem. Mol. Biol. 2020, 0021-9258.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.157
Kód RIV RIV/00216224:14160/20:00118106
Organizační jednotka Farmaceutická fakulta
Doi http://dx.doi.org/10.1074/jbc.RA120.012659
UT WoS 000550698000020
Klíčová slova anglicky sphingosine kinase; cholesterol; Niemann?Pick type C; sphingolipids; lysosomal storage disease; genetic disorder; lipid metabolism; neurodegeneration; sphingolipid; sphingosine kinase (SphK); sphingosine-1-phosphate (S1P); NPC1
Štítky rivok, ÚChL
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Hana Hurtová, učo 244985. Změněno: 24. 2. 2021 08:25.
Anotace
Niemann?Pick type C (NPC) disease is a lysosomal storage disorder arising from mutations in the cholesterol-trafficking protein NPC1 (95%) or NPC2 (5%). These mutations result in accumulation of low-density lipoprotein-derived cholesterol in late endosomes/lysosomes, disruption of endocytic trafficking, and stalled autophagic flux. Additionally, NPC disease results in sphingolipid accumulation, yet it is unique among the sphingolipidoses because of the absence of mutations in the enzymes responsible for sphingolipid degradation. In this work, we examined the cause for sphingosine and sphingolipid accumulation in multiple cellular models of NPC disease and observed that the activity of sphingosine kinase 1 (SphK1), one of the two isoenzymes that phosphorylate sphingoid bases, was markedly reduced in both NPC1 mutant and NPC1 knockout cells. Conversely, SphK1 inhibition with the isotype-specific inhibitor SK1-I in WT cells induced accumulation of cholesterol and reduced cholesterol esterification. Of note, a novel SphK1 activator (SK1-A) that we have characterized decreased sphingoid base and complex sphingolipid accumulation and ameliorated autophagic defects in both NPC1 mutant and NPC1 knockout cells. Remarkably, in these cells, SK1-A also reduced cholesterol accumulation and increased cholesterol ester formation. Our results indicate that a SphK1 activator rescues aberrant cholesterol and sphingolipid storage and trafficking in NPC1 mutant cells. These observations highlight a previously unknown link between SphK1 activity, NPC1, and cholesterol trafficking and metabolism.
VytisknoutZobrazeno: 21. 7. 2024 12:20